A global contract research organization (CRO) based in Ireland has won a major U.S. government contract associated with the war on COVID-19. ICON Plc, (NASDAQ: ICLR), a global provider of outsourced drug and device development and commercialization services to pharmaceutical, biotechnology, medical device industries and government and public health organizations, has been re-selected by the Biomedical Advanced Research and Development Authority (BARDA) to continue being part of its exclusive Medical Countermeasures Clinical Studies Network (CSN).
Mission-Critical Government-Funded Activity
BARDA, part of the Office of the Assistant Secretary for Preparedness and Response within the U.S. Department of Health and Human Services, is responsible for developing medical countermeasures to secure the U.S. against chemical, biological, radiological, and nuclear threats, as well as pandemic influenza and emerging infectious diseases. The CSN provides BARDA partners with vital technical and regulatory assistance to develop vaccines, therapeutics, diagnostics, and medical devices to prevent or treat the medical consequences of these threats.
ICON continues to be a part of...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).